Top 5 stories on the search for an HIV cure from CROI 2026 The search for a way to control HIV without antiretroviral therapy (ART) continued to generate both promising signals and sobering setbacks at the recent Conference on Retroviruses and Opportunistic I...

There is still no cure for HIV - although a handful of people have been cured.
My comrades at @aidsmap.bsky.social have collected the top stories on cure research - some promising, some disappointing - from the recent #CROI2026 conference.

La PrEP sigue sin llegar a suficiente gente y los recortes la frenan aún más.

Sin acceso masivo, el VIH podría estancarse en 1,4 millones de casos anuales.

📲 Lee «La Noticia del Día» de gTt-VIH 🧡

🔗 www.gtt-vih.org/publicacione...

#CROI2026

The latest @iasusa-official.bsky.social podcast features Dr. Frater who shared a presentation at #CROI2026 that explored strategies for targeting the reservoir of latent #HIV infection in treated individuals, with a specific interest in primary HIV infection. Watch here: iasusa.org/2026/04/07/g...

CROI 2026 refuerza el papel de las células CD8 en el control del VIH.

Algunas mantienen su función pese a la infección prolongada, lo que abre nuevas vías hacia una cura funcional.

📲 Lee «La Noticia del Día» de gTt-VIH 🧡

🔗 www.gtt-vih.org/publicacione...

#CROI2026

New Podcast Available: Episode 74 - Immunology of HIV Cure and Beyond: Navigating Immunology Presentations at CROI 2026 with Dr John Frater (April 7, 2026). www.iasusa.org/2026/04/07/g... #IASUSA #CROI2026

Top 5 stories on HIV prevention and sexual health from CROI 2026 From a contested study on U=U to a disappointing gonorrhoea vaccine trial and the ongoing global PrEP crisis, HIV prevention was a key topic at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver. Here are five highlights.

From a contested study on U=U to a disappointing gonorrhoea vaccine trial and the ongoing global PrEP crisis, HIV prevention was a key topic at CROI 2026 in Denver. Here are five highlights. #CROI2026

Top 5 stories on long-term health for people living with HIV from CROI 2026 As more people live longer with HIV, managing other health conditions is increasingly important. Research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver covered a wide range of issues – from new obesity drugs and cardiovascular risk to transplant outcomes and stimulant drug use. Here are five highlights.

As more people live longer with HIV, managing other health conditions is increasingly important. Research at #CROI2026 covered a wide range of issues, including new obesity drugs and cardiovascular risk.

Top 5 stories on the future of HIV treatment from CROI 2026 The HIV treatment landscape is changing fast. Research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver pointed towards a future of fewer pills, less frequent dosing and new drug classes – from twice-yearly injectables to a simplified regimen for people on complex treatment. Here are five highlights.

The HIV treatment landscape is changing fast. Research presented at #CROI2026 pointed towards a future of fewer pills, less frequent dosing and new drug classes. Here are five highlights.

The untapped potential of CD8 cells: how cellular immunity may be the key to an HIV cure Several presentations at last month’s Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, US provided hope for the development of therapeutic vaccinations as well as T-cell and antibody therapies that could lead to long-term control or even a cure for HIV. It had been thought that HIV infection, especially long-term infection, exhausts the immune cells that normally fight infections, leading to a state of immune ‘senescence’ (premature ageing) and long-term, low-level inflammation.

News from CROI 2026: The untapped potential of CD8 cells: how cellular immunity may be the key to an HIV cure #CROI2026

GLP-1 agonists could be a global game-changer, but need to be accessible and affordable Popular GLP-1 weight-loss medications generally work well for people living with HIV, and they may improve liver, gut and cardiovascular health and reduce smoking, along with their well-known benefits for obesity and diabetes, according to studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2026). However, much remains to be learned about their long-term use.

News from CROI 2026: GLP-1 agonists could be a global game-changer, but need to be accessible and affordable #CROI2026

In This Moment of Crisis, Peter Staley Urges the HIV Community to Act Together In a moment defined by fear and uncertainty, the prominent longtime HIV activist offers a roadmap for resistance—from professional societies to the streets—and calls on the HIV community to act togeth...

🧵1️⃣ #HIV-Aktivist Peter Staley, Gründer der Treatment Action Group und von PrEP4All, hat bei seiner eindrucksvollen Eröffnungsrede auf der #CROI2026 eine Verbindung zwischen den frühen Kämpfen von #ACTUP und den heutigen koordinierten politischen Angriffen auf die Wissenschaft gezogen. /2

Los agonistas del GLP-1 podrían mejorar peso, metabolismo y riesgo cardiovascular en personas con el VIH.

La evidencia avanza. El reto es que llegue a quienes la necesitan.

📲 Lee «La Noticia del Día» de gTt-VIH 🧡

🔗 www.gtt-vih.org/publicacione...

#CROI2026

Un estudio estima un riesgo muy bajo de transmisión del VIH con carga viral baja (~200 copias).

La evidencia sigue siendo clara: con carga viral indetectable, el VIH no se transmite (I=I).

📲 Lee «La Noticia del Día» de gTt-VIH 🧡

🔗 www.gtt-vih.org/publicacione...

#CROI2026

Colourful i-Base graphic. The main text reads: First new HSV drug class in years will be submitted for FDA approval this quarter. In the top left is i-Base’s website address: I hyphen base dot info. A smaller rectangle in the bottom right, reads: HIV news. 2026. CROI 2026, is in the top right corner with CROI’s logo, a colourful illustration of the HIV virus. At the bottom, text reads, Denver, Colorado. February 22nd to 25th. Large colourful virus illustrations are faintly seen in the background of the image. The colours used in the image are pale blue, pale green, orange, dark blue, purple, turquoise, yellow, white, pink, green and black.

Pritelivir active against drug-resistant #herpes in phase 3 study:

i-base.info/htb/53453

The US FDA has given #pritelivir Breakthrough Indication designation, with submission of a New Drug Indication expected by the end of March.

#CROI2026 #HIV #HSV #CureHerpes #IDsky #HIVsky #GUMsky

Jeanne Marrazzo, M.D., M.P.H.: CROI 2026 Highlights and the Future of HIV Care Newly appointed IDSA CEO (and former NIAID Director) Jeanne Marrazzo, M.D., M.P.H., discusses a wide array of important topics of the day that stand at the intersection of HIV research, clinical care, and policy/politics.

IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, is a guest on TheBodyPro’s The Future of HIV Care podcast, where she reflects on #CROI2026 highlights, new data on DoxyPEP and long-acting prevention tools, and the role of IDSA and HIVMA in advancing HIV clinical guidance. https://bit.ly/41dZXpz

More data support investigational drug combo for HIV therapy DENVER — A novel regimen of doravirine and islatravir was noninferior to a common HIV therapy as an initial HIV treatment, according to phase 3 data shared at the Conference on Opportunistic Infections and Retroviruses.“Over time, people may need to adjust their HIV treatment regimens because of comorbidities, concerns about toxicities, tolerability challenges or a desire for regimens

#HIV regimen of doravirine and islatravir “has the potential to be a new integrase strand transfer inhibitor-free option for people living with HIV,” says Jürgen K. Rockstroh, MD, who presented data at #CROI2026.

vist.ly/4w5du

From advancing access to #lenacapavir for #PrEP in Zambia to mobilizing global advocacy for #HIV research and translating science at #CROI2026, see how AVAC's advocacy is driving impact.

Read more: avac.org/blog/the-imp...

CROI 2026 Update: New HIV Prevention and Syndemic Coinfection Data Aniruddha (Anu) Hazra, M.D., recaps some of the PrEP trial results he found most interesting—as well as a few studies on common coinfections seen in people living with HIV.

Aniruddha (Anu) Hazra, M.D., recaps some of the PrEP trial results he found most interesting—as well as a few studies on common coinfections seen in people living with HIV. #croi2026 #hivski #idsky

www.thebodypro.com/video/hiv/cr...

New Podcast Available: Episode 72 - Neurodegeneration and Dementia Risk in Older Adults with HIV: Biomarkers and Epidemiology with Dr Alan Winston (March 24, 2026) www.iasusa.org/2026/03/24/g... #IASUSA #CROI2026

More data support investigational drug combo for HIV therapy DENVER — A novel regimen of doravirine and islatravir was noninferior to a common HIV therapy as an initial HIV treatment, according to phase 3 data shared at the Conference on Opportunistic Infections and Retroviruses.“Over time, people may need to adjust their HIV treatment regimens because of comorbidities, concerns about toxicities, tolerability challenges or a desire for regimens

#HIV therapy regimen of doravirine and islatravir has "potential to be a new integrase strand transfer inhibitor-free option for people living with HIV,” says Jürgen K. Rockstroh, MD, who presented at #CROI2026. Read ⬇

vist.ly/4vz5j

Join the “In Case You Missed It: Scientific Report Back from the 2026 Conference on Retroviruses and Opportunistic Infections” on April 29, 2026, at 1 PM PT. The purpose of this #ICYMI is to provide an expert-led overview of key scientific updates presented at #CROI2026. Register: t.co/lZTT17oKmh

Cabotegravir + anticuerpo logran mantener el VIH controlado tras un año.

Resultados de CROI 2026 apuntan a tratamientos más espaciados y adaptados a la vida real.

📲 Lee «La Noticia del Día» de gTt-VIH 🧡

🔗 www.gtt-vih.org/publicacione...

#CROI2026

CROI 2026: Full coverage The 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) took place in Denver, US, on 22-25 February 2026.

#CROI2026 highlights in one place.

Read EATG’s HIV & co-infections round-up:
👉 www.eatg.org/hiv-news/cro...

📩 Subscribe for updates:
👉 eepurl.com/b582Sn

🚨 #HIVCure resource alert!

What’s next in the journey toward an #HIV cure?

🎥 Watch key #CROI2026 takeaways with Alison Agwu: www.youtube.com/watch?v=fbTg...

📄 Read the latest from AVAC's Jessica Salzwedel + partners on pediatric HIV cure: academic.oup.com/jpids/articl...

#PAVECollaboratory

Missed CROI this year? Catch up with the research from the conference on aidsmap.com, with our news articles, summary bulletins and video interviews. #CROI2026
https://www.aidsmap.com/conferences/croi-2026

La triple infección por VHB, VHD y VIH aumenta el riesgo de enfermedad hepática grave.
Datos de #CROI2026 refuerzan la necesidad de mejorar el cribado y el acceso a tratamiento, especialmente para hepatitis D.

📲 Lee «La Noticia del Día» de gTt-VIH 🧡

🔗 gtt-vih.org/publicacione...

Nuevos datos en #CROI2026 sobre hacia dónde avanza la investigación en VIH.
Los resultados aún son limitados y no permiten controlar el virus sin tratamiento.
El foco se desplaza hacia estrategias combinadas.

📲 Lee «La Noticia del Día» de gTt-VIH 🧡

Colourful i-Base graphic. The main text reads: New study of MenB vaccine shows zero protection for gay men against gonorrhoea. In the top left is i-Base’s website address: I hyphen base dot info. A smaller rectangle in the bottom right, reads: HIV news. 2026. CROI 2026, is in the top right corner with CROI’s logo, a colourful illustration of the HIV virus. At the bottom, text reads, Denver, Colorado. February 22nd to 25th. Large colourful virus illustrations are faintly seen in the background of the image. The colours used in the image are pale blue, pale green, orange, dark blue, purple, turquoise, yellow, white, pink, green and black.

Study of #4CMenB #vaccine in #Australia fails to protect gay men against #gonorrhoea:

i-base.info/htb/53465

Will other study results be more positive or do we need a better vaccine?

#CROI2026 #GUMsky #IDsky #STI #SexualHealth #gonorrhea #GonorrhoeaVaccine #LoveGUM #STIprevention #STIawareness

Can someone transmit HIV with a viral load of 200? Ugandan study re-ignites the U=U debate The presentation of a study at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver caused consternation when it appeared to contradict data that have served as the basis for the ‘Undetectable equals Untransmittable’ (U=U) campaign, which informs people with HIV that they cannot pass on HIV during sex if they have an ‘undetectable’ viral load – defined in the foundational studies as below 200.

News from CROI 2026: Can someone transmit HIV with a viral load of 200? Ugandan study re-ignites the U=U debate #CROI2026 #UequalsU

Younger, mobile men especially likely to not know they have HIV in eastern and southern Africa One in seven men living with HIV in eastern and southern Africa are unaware that they have the virus, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, US by Dr Craig Heck of Columbia University. Younger men and those who sometimes live away from home were more likely not to know their status.

News from CROI 2026: Younger, mobile men especially likely to not know they have HIV in eastern and southern Africa #CROI2026